Literature DB >> 22415710

Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.

Thangirala Sudha1, Patricia Phillips, Camille Kanaan, Robert J Linhardt, Lubor Borsig, Shaker A Mousa.   

Abstract

Metastasis is the most devastating aspect of cancer and it is the main cause of morbidity and mortality in cancer patients. Tumor cell adhesion to the vascular endothelial cell lining is an important step in metastatic progression and is prompted by platelets. Mucin 1 is over-expressed and aberrantly glycosylated in more than 60% of pancreatic ductal adeno-carcinomas, which mediate adhesion of pancreatic cancer cells to platelets via P-selectin. The anticoagulant low molecular weight heparins (LMWHs), which are commonly used in venous Thromboprophylaxis and treatment, appear to have an effect on cancer survival. The aim of this study is to investigate the effect of platelets on human pancreatic cancer MPanc96 cell adhesion to the endothelial cell vessel wall, and to examine the effect of heparin derivatives on MPanc96 adhesion using a novel, in vitro model of human umbilical cord vein. The modified heparin S-NACH (sulfated non-anticoagulant heparin), which is devoid of antithrombin (AT) binding and devoid of inhibition of systemic AT-dependent coagulation factors such as factor Xa and IIa, and the LMWH tinzaparin both potently reduced adhesion and invasion of fluorescence-labeled MPanc96 cancer cells to the endothelial layer of umbilical cord vein in a dose-dependent manner. S-NACH effectively inhibited P-selectin mediated MPanc96 cell adhesion, and inhibited cell adhesion and invasion similar to tinzaparin, indicating that systemic anticoagulation is not a necessary component for heparin attenuation of cancer cell adhesion, invasion, and metastasis. Also, S-NACH and tinzaparin versus unfractionated heparin, heparin derivatives enoxaparin, deltaparin, fraxiparin, and fondaparinux were evaluated for their effect on platelet-cancer cell adhesion. An in vivo anti-metastatic S-NACH-treated nude mouse model of MPanc96 pancreatic cancer cell metastasis demonstrated potent anti-metastasis efficacy as evidenced by IVIS imaging and histological staining.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22415710     DOI: 10.1007/s10585-012-9461-9

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  32 in total

1.  Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.

Authors:  D Green; R D Hull; R Brant; G F Pineo
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 3.  Inhibition of metastases by anticoagulants.

Authors:  M Hejna; M Raderer; C C Zielinski
Journal:  J Natl Cancer Inst       Date:  1999-01-06       Impact factor: 13.506

4.  Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.

Authors:  Anthony Maraveyas; Camille Ettelaie; Hussein Echrish; Chao Li; Eric Gardiner; John Greenman; Leigh A Madden
Journal:  Blood Coagul Fibrinolysis       Date:  2010-07       Impact factor: 1.276

5.  Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists.

Authors:  Noëlia Gomes; Jany Vassy; Claude Lebos; Brigitte Arbeille; Chantal Legrand; Françoise Fauvel-Lafeve
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth.

Authors:  Michael Kragh; Lise Binderup; Pernille-Julia Vig Hjarnaa; Erik Bramm; Kristian B Johansen; Christian Frimundt Petersen
Journal:  Oncol Rep       Date:  2005-07       Impact factor: 3.906

7.  The effect of low molecular weight heparin on survival in patients with advanced malignancy.

Authors:  Clara P W Klerk; Susanne M Smorenburg; Hans-Martin Otten; Anthonie W A Lensing; Martin H Prins; Franco Piovella; Paolo Prandoni; Monique M E M Bos; Dick J Richel; Geertjan van Tienhoven; Harry R Büller
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

Review 8.  Low-molecular-weight heparin in thrombosis and cancer.

Authors:  Shaker A Mousa
Journal:  Semin Thromb Hemost       Date:  2004-02       Impact factor: 4.180

9.  Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma.

Authors:  Stefan von Delius; Muhammed Ayvaz; Stefan Wagenpfeil; Florian Eckel; Roland M Schmid; Christian Lersch
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316

View more
  16 in total

1.  Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.

Authors:  Joanne W Chiu; Hilda Wong; Roland Leung; Roberta Pang; Tan-To Cheung; Sheung-Tat Fan; Ronnie Poon; Thomas Yau
Journal:  Oncologist       Date:  2014-08-12

Review 2.  Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease.

Authors:  Yi-Pin Lin; Lingyun Li; Fuming Zhang; Robert J Linhardt
Journal:  Microbiology       Date:  2017-11-08       Impact factor: 2.777

Review 3.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

4.  Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.

Authors:  Priya Samuel; Laura Ann Mulcahy; Fiona Furlong; Helen O McCarthy; Susan Ann Brooks; Muller Fabbri; Ryan Charles Pink; David Raul Francisco Carter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

5.  Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells.

Authors:  Yang Zhao; Daohai Zhang; Sheng Wang; Li Tao; Aiyun Wang; Wenxing Chen; Zhijie Zhu; Shizhong Zheng; Xiang Gao; Yin Lu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 6.  Heparin: Past, Present, and Future.

Authors:  Eziafa I Oduah; Robert J Linhardt; Susan T Sharfstein
Journal:  Pharmaceuticals (Basel)       Date:  2016-07-04

Review 7.  Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles.

Authors:  Sara Salatin; Ahmad Yari Khosroushahi
Journal:  J Cell Mol Med       Date:  2017-02-28       Impact factor: 5.310

Review 8.  Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease.

Authors:  Erik G Hayman; Akil P Patel; Robert F James; J Marc Simard
Journal:  Molecules       Date:  2017-05-02       Impact factor: 4.411

Review 9.  Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.

Authors:  Cinzia Lanzi; Giuliana Cassinelli
Journal:  Molecules       Date:  2018-11-08       Impact factor: 4.411

10.  Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway.

Authors:  Mohamed A Ghonim; Jeffrey Wang; Salome V Ibba; Hanh H Luu; Kusma Pyakurel; Ilyes Benslimane; Shaker Mousa; A Hamid Boulares
Journal:  J Transl Med       Date:  2018-09-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.